Home The Word Brain	My Amedeo FAQ Privacy About
	Amedeo C49 English + 你好 (nǐ hǎo) = limitless possibilities. Start learning Mandarin Chinese today—for free, forever. Amedeo C49 is completely free, for life. Next week: +49.

Ovarian Neoplasms

Free Subscription Articles published in PLoS One Retrieve available abstracts of 73 articles: HTML format

Single Articles

January 2025
1. LEE B, Chang SJ, Kwon BS, Son JH, et al
   Correction: Impact of PARP inhibitor maintenance therapy in newly diagnosed advanced epithelial ovarian cancer: A meta-analysis.
   PLoS One. 2025;20:e0317158.
   PubMed     Abstract available
   
   
   
2. TJOKROPRAWIRO BA, Novitasari K, Ulhaq RA, Sulistya HA, et al
   Investigation of the trends and associated factors of ovarian cancer in Indonesia: A systematic analysis of the Global Burden of Disease study 1990-2021.
   PLoS One. 2025;20:e0313418.
   PubMed     Abstract available
   
   
   
3. TAL O, Zahavi T, Sinberger LA, Salmon-Divon M, et al
   Unlocking prognostic potential: A genomic signature of caloric restriction in patients with epithelial ovarian cancer.
   PLoS One. 2025;20:e0317502.
   PubMed     Abstract available
   
   
   
4. ZHANG J, Gangwar S, Bano N, Ahmad S, et al
   Probing the role of Coniferin and Tetrahydrocurcumin from Traditional Chinese medicine against PSAT1 in early-stage ovarian cancer: An in silico study.
   PLoS One. 2025;20:e0313585.
   PubMed     Abstract available
   
   
   
5. LI S, Wang Z, Huang HD
   Deciphering ovarian cancer heterogeneity through spatial transcriptomics, single-cell profiling, and copy number variations.
   PLoS One. 2025;20:e0317115.
   PubMed     Abstract available
   
   
   
6. ALIZADEH H, Kerachian S, Babashah S, Soltani BM, et al
   Introduction of AGPAT3 gene as a regulator of cisplatin resistance in A2780 ovarian endometrioid carcinoma cell line.
   PLoS One. 2025;20:e0318740.
   PubMed     Abstract available
   
   
   
7. DE AMORIM IFG, Melo CPS, Pereira RA, Cunha SM, et al
   Association of a CHEK2 somatic variant with tumor microenvironment calprotectin expression predicts platinum resistance in a small cohort of ovarian carcinoma.
   PLoS One. 2025;20:e0315487.
   PubMed     Abstract available
   
   
   
8. BAO Q, Wang Z, Yang T, Su X, et al
   Curcumin induces mitochondrial dysfunction-associated oxidative DNA damage in ovarian cancer cells.
   PLoS One. 2025;20:e0319846.
   PubMed     Abstract available
   
   
   
9. NIU P, Li D, Chen H, Zhu Y, et al
   Cardamonin suppresses mTORC1/SREBP1 through reducing Raptor and inhibits de novo lipogenesis in ovarian cancer.
   PLoS One. 2025;20:e0322733.
   PubMed     Abstract available
   
   
   
10. FRISK NLS, Jorgensen MM, Baek R, Atic AI, et al
    Characterization of small extracellular vesicles from ovarian cancer patients and pre-diagnostic patient samples: Evidence from the Danish blood donor study.
    PLoS One. 2025;20:e0323529.
    PubMed     Abstract available
    
    
    
11. ANGELES A, Khazamipour N, Dhillon G, Janfaza S, et al
    Matching plasma and tissue miRNA expression analysis to detect viable ovarian germ cell tumors.
    PLoS One. 2025;20:e0322477.
    PubMed     Abstract available
    
    
    
12. PHILIBERT R, Beach SRH, Mills JA, Dawes K, et al
    Epigenetic assessments of alcohol consumption predict mortality in smokers at risk for lung cancer in the prostate, lung, colorectal and ovarian cancer screening trial.
    PLoS One. 2025;20:e0322783.
    PubMed     Abstract available
    
    
    
13. KIM TH, Memarzadeh S, Vahdatshariatpanahi S, Ostrzega N, et al
    Significance of androgen receptor and its potential for anti-androgen/androgen receptor-antagonist therapy in ovarian cancers.
    PLoS One. 2025;20:e0322744.
    PubMed     Abstract available
    
    
    
14. MA S, Zhou L, Liu Y, Jie H, et al
    Identification of a novel chemotherapy benefit index for patients with advanced ovarian cancer based on Bayesian network analysis.
    PLoS One. 2025;20:e0322130.
    PubMed     Abstract available
    
    
    
15. MA Z, Dang R, Wu G
    KU60019 inhibits ovarian cancer progression by targeting DGAT1/has-miR-1273g-3p axis.
    PLoS One. 2025;20:e0325213.
    PubMed     Abstract available
    
    
    
16. ZAKI RM, Aldosari BN, Alkharashi LA, Alsalhi A, et al
    Fabrication and appraisal of axitinib loaded PEGylated spanlastics against MCF- 7 and OV- 2774 cell lines using molecular docking methods and in-vitro study.
    PLoS One. 2025;20:e0325055.
    PubMed     Abstract available
    
    
    
17. ZAKI RM, Aldosari BN, Alkharashi LA, Alsalhi A, et al
    Fabrication and appraisal of targeted axitinib loaded bilosomes for the enhanced breast and ovarian anticancer activity.
    PLoS One. 2025;20:e0325511.
    PubMed     Abstract available
    
    
    
18. DURANTE V, Wittwer A, Theek B, Martinez-Osuna M, et al
    Precision-cut tumor tissue slices, a novel tool to study the tumor microenvironment interactions with chimeric antigen receptor (CAR) T cells.
    PLoS One. 2025;20:e0327322.
    PubMed     Abstract available
    
    
    
19. ADISU MA, Habtie TE, Kitaw TA, Gessesse AD, et al
    The rising burden of female cancer in Ethiopia (2000-2021) and projections to 2040: Insights from the global burden of disease study.
    PLoS One. 2025;20:e0333787.
    PubMed     Abstract available
    
    
    January 2024
20. YOO MY, Woo KJ, Kang SY, Moon BS, et al
    Efficacy of preoperative lymphoscintigraphy in predicting surgical outcomes of lymphaticovenous anastomosis in lower extremity lymphedema: Clinical correlations in gynecological cancer-related lymphedema.
    PLoS One. 2024;19:e0296466.
    PubMed     Abstract available
    
    
    
21. WANG G, Fu J, Liu M, Zheng Q, et al
    CXC chemokines: Potential biomarker and immunotherapeutic target for uterine corpus endometrial carcinoma.
    PLoS One. 2024;19:e0277872.
    PubMed     Abstract available
    
    
    
22. 
    Expression of Concern: Minocycline Suppresses Interleukine-6, Its Receptor System and Signaling Pathways and Impairs Migration, Invasion and Adhesion Capacity of Ovarian Cancer Cells: In Vitro and In Vivo Studies.
    PLoS One. 2024;19:e0298444.
    PubMed    
    
    
    
23. YONG CM, Yehgambaram PAP, Lee SWH
    Cost-effectiveness analysis of olaparib maintenance therapy for BRCA mutation ovarian cancer in the public sector in Malaysia.
    PLoS One. 2024;19:e0298130.
    PubMed     Abstract available
    
    
    
24. DING H, Hu B, Guo R
    Comprehensive analysis of single cell and bulk data develops a promising prognostic signature for improving immunotherapy responses in ovarian cancer.
    PLoS One. 2024;19:e0298125.
    PubMed     Abstract available
    
    
    
25. MIKHAEL S, Kurdi A, Khoueiry-Zgheib N, Tahtouh R, et al
    Evaluating synergistic effects of metformin and simvastatin on ovarian cancer cells.
    PLoS One. 2024;19:e0298127.
    PubMed     Abstract available
    
    
    
26. KANG J, Na K, Kang H, Cho U, et al
    Prediction of homologous recombination deficiency from Oncomine Comprehensive Assay Plus correlating with SOPHiA DDM HRD Solution.
    PLoS One. 2024;19:e0298128.
    PubMed     Abstract available
    
    
    
27. LI L, He L, Guo W, Ma J, et al
    PMFFNet: A hybrid network based on feature pyramid for ovarian tumor segmentation.
    PLoS One. 2024;19:e0299360.
    PubMed     Abstract available
    
    
    
28. CHEN Z, Wang C, Ding J, Yu T, et al
    Construction and analysis of competitive endogenous RNA networks and prognostic models associated with ovarian cancer based on the exoRBase database.
    PLoS One. 2024;19:e0291149.
    PubMed     Abstract available
    
    
    
29. MEHRA T, Lupatsch JE, Kossler T, Dedes K, et al
    Olaparib not cost-effective as maintenance therapy for platinum-sensitive, BRCA1/2 germline-mutated metastatic pancreatic cancer.
    PLoS One. 2024;19:e0301271.
    PubMed     Abstract available
    
    
    
30. LI N, Jin S, Wu J, Ji H, et al
    Effect of different treatment modalities on ovarian cancer patients with liver metastases: A retrospective cohort study based on SEER.
    PLoS One. 2024;19:e0299504.
    PubMed     Abstract available
    
    
    
31. REID F, Adams T, Adel RS, Andrade CE, et al
    The every woman study low- and middle-income countries edition protocol: A multi-country observational study to assess opportunities and challenges to improving survival and quality of life for women with ovarian cancer.
    PLoS One. 2024;19:e0298154.
    PubMed     Abstract available
    
    
    
32. PARK K, Kwon JY, Song JM, Pyeon SY, et al
    Prognostic impact of suspicious extraabdominal lymph nodes on patient survival in advanced ovarian cancer.
    PLoS One. 2024;19:e0299205.
    PubMed     Abstract available
    
    
    
33. HOSOKAWA S, Norimatsu Y, Shinagawa A, Kurokawa T, et al
    Assessment of the localization of chondroitin sulfate in various types of endometrial carcinoma.
    PLoS One. 2024;19:e0304420.
    PubMed     Abstract available
    
    
    
34. KIM NK, Suh DH, Kim K, No JH, et al
    High-throughput viable circulating tumor cell isolation using tapered-slit membrane filter-based chipsets in the differential diagnosis of ovarian tumors.
    PLoS One. 2024;19:e0304704.
    PubMed     Abstract available
    
    
    
35. KARSTENSEN S, Kaiser K, Moos C, Poulsen TS, et al
    DNA alterations in ovarian adult granulosa cell tumours: A scoping review protocol.
    PLoS One. 2024;19:e0303989.
    PubMed     Abstract available
    
    
    
36. NUNEZ-RIOS JD, Reyna-Jeldes M, Mata-Martinez E, Campos-Contreras ADR, et al
    Extracellular ATP/P2X7 receptor, a regulatory axis of migration in ovarian carcinoma-derived cells.
    PLoS One. 2024;19:e0304062.
    PubMed     Abstract available
    
    
    
37. JANG DH, Lee HG, Lee B, Kang S, et al
    Prediction of final pathology depending on preoperative myometrial invasion and grade assessment in low-risk endometrial cancer patients: A Korean Gynecologic Oncology Group ancillary study.
    PLoS One. 2024;19:e0305360.
    PubMed     Abstract available
    
    
    
38. ZHAO S, Wang L, Ouyang M, Xing S, et al
    Polyploid giant cancer cells induced by Docetaxel exhibit a senescence phenotype with the expression of stem cell markers in ovarian cancer cells.
    PLoS One. 2024;19:e0306969.
    PubMed     Abstract available
    
    
    
39. ANCHOORI RK, Tseng SH, Tsai HL, Palande V, et al
    Preclinical studies of RA475, a guanidine-substituted spirocyclic candidate RPN13/ADRM1 inhibitor for treatment of ovarian cancer.
    PLoS One. 2024;19:e0305710.
    PubMed     Abstract available
    
    
    
40. MA MC, Lavi ES, Altwerger G, Lin ZP, et al
    Predictive modeling of gene mutations for the survival outcomes of epithelial ovarian cancer patients.
    PLoS One. 2024;19:e0305273.
    PubMed     Abstract available
    
    
    
41. CARTER R, Petrik JJ, Moorehead RA
    Overexpression of miR-200s inhibits proliferation and invasion while increasing apoptosis in murine ovarian cancer cells.
    PLoS One. 2024;19:e0307178.
    PubMed     Abstract available
    
    
    
42. PATRA A, Ali SS, Devi NM, Qadeer AS, et al
    Prevalence of BRCA mutation in breast and ovarian cancer among women in India: A systematic review and meta-analysis protocol.
    PLoS One. 2024;19:e0306612.
    PubMed     Abstract available
    
    
    
43. TANG F, Hummitzsch K, Rodgers RJ
    Unique features of KGN granulosa-like tumour cells in the regulation of steroidogenic and antioxidant genes.
    PLoS One. 2024;19:e0308168.
    PubMed     Abstract available
    
    
    
44. HOLMLUND S, Collins E, Lalos A, Idahl A, et al
    From symptoms to surgery-A pathway through uncertainty and hope: An interview study of women facing ovarian surgery.
    PLoS One. 2024;19:e0307666.
    PubMed     Abstract available
    
    
    
45. ISINGIZWE ZR, Mortan LF, Benbrook DM
    Platelet and epithelial cell interations can be modeled in cell culture, and are not affected by dihomo-gamma-linolenic acid.
    PLoS One. 2024;19:e0309125.
    PubMed     Abstract available
    
    
    
46. KAUTZ-FREIMUTH S, Lautz Z, Shukri A, Redaelli M, et al
    Decisional conflict and knowledge in women with BRCA1/2 pathogenic variants: An exploratory age group analysis of a randomised controlled decision aid trial.
    PLoS One. 2024;19:e0311432.
    PubMed     Abstract available
    
    
    
47. YOSHIDA-COURT K, Karpinets TV, Mitra A, Solley TN, et al
    Correction: Immune environment and antigen specificity of the T cell receptor repertoire of malignant ascites in ovarian cancer.
    PLoS One. 2024;19:e0314643.
    PubMed     Abstract available
    
    
    
48. MOGI K, Yoshihara M, Emoto R, Miyamoto E, et al
    Histology-specific long-term oncologic outcomes in patients with epithelial ovarian cancer who underwent complete tumor resection: The implication of occult seeds after initial surgery.
    PLoS One. 2024;19:e0311421.
    PubMed     Abstract available
    
    
    
49. KIM K, Khazan N, McDowell JL, Snyder CWA, et al
    The NF-kappaB-HE4 axis: A novel regulator of HE4 secretion in ovarian cancer.
    PLoS One. 2024;19:e0314564.
    PubMed     Abstract available
    
    
    
50. WEINSTEIN SJ, Parisi D, Mondul AM, Layne TM, et al
    Vitamin D binding protein genetic isoforms, serum vitamin D, and cancer risk in the Prostate, Lung, Colorectal, and Ovarian (PLCO) Cancer Screening Trial.
    PLoS One. 2024;19:e0315252.
    PubMed     Abstract available
    
    
    
51. RUSSO D, Spina A, Portella L, Bello AM, et al
    The CXCR4 antagonist R54 targets epithelial-mesenchymal transition (EMT) in human ovarian cancer cells.
    PLoS One. 2024;19:e0314735.
    PubMed     Abstract available
    
    
    
52. PERAMPALAM P, McDonald JI, Dick FA
    GO-CRISPR: A highly controlled workflow to discover gene essentiality in loss-of-function screens.
    PLoS One. 2024;19:e0315923.
    PubMed     Abstract available
    
    
    
53. SENGUPTA D, Ali SN, Bhattacharya A, Mustafi J, et al
    Correction: A deep hybrid learning pipeline for accurate diagnosis of ovarian cancer based on nuclear morphology.
    PLoS One. 2024;19:e0316114.
    PubMed     Abstract available
    
    
    
54. WANG H, Han X, Niu S, Cheng H, et al
    DFASGCNS: A prognostic model for ovarian cancer prediction based on dual fusion channels and stacked graph convolution.
    PLoS One. 2024;19:e0315924.
    PubMed     Abstract available
    
    
    
55. LOPACINSKA-JORGENSEN J, Oliveira DVNP, Novotny GW, Hogdall CK, et al
    Correction: Integrated microRNA and mRNA signatures associated with overall survival in epithelial ovarian cancer.
    PLoS One. 2024;19:e0315859.
    PubMed     Abstract available
    
    
    January 2023
56. HAWARDEN A, Price M, Russell B, Wilson G, et al
    A three protein signature fails to externally validate as a biomarker to predict surgical outcome in high-grade epithelial ovarian cancer.
    PLoS One. 2023;18:e0281798.
    PubMed     Abstract available
    
    
    
57. JLASSI A, Manai M, Morjen M, Sahraoui G, et al
    VISTA+/CD8+ status correlates with favorable prognosis in Epithelial ovarian cancer.
    PLoS One. 2023;18:e0278849.
    PubMed     Abstract available
    
    
    
58. EBRING C, Marlin R, Macni J, Vallard A, et al
    Type II endometrial cancer: Incidence, overall and disease-free survival in Martinique.
    PLoS One. 2023;18:e0278757.
    PubMed     Abstract available
    
    
    
59. NUNES PEREIRA P, Francoise Derchain S, Yoshida A, Hoelz de Oliveira Barros R, et al
    Diffusion-weighted magnetic resonance sequence and CA125/CEA ratio can be used as add-on tools to ultrasound for the differentiation of ovarian from non-ovarian pelvic masses.
    PLoS One. 2023;18:e0283212.
    PubMed     Abstract available
    
    
    
60. GOLDSBURY DE, Vassallo A, Weber MF, Steinberg J, et al
    Health services costs for ovarian cancer in Australia: Estimates from the 45 and Up Study.
    PLoS One. 2023;18:e0282851.
    PubMed     Abstract available
    
    
    
61. KIM NK, Suh DH, Kim K, Kim YB, et al
    Feasibility of extended cycles of neoadjuvant chemotherapy in patients with advanced ovarian cancer in terms of prognosis and surgical outcomes.
    PLoS One. 2023;18:e0284753.
    PubMed     Abstract available
    
    
    
62. LOPACINSKA-JORGENSEN J, Petersen PHD, Oliveira DVNP, Hogdall CK, et al
    Strategies for data normalization and missing data imputation and consequences for potential diagnostic microRNA biomarkers in epithelial ovarian cancer.
    PLoS One. 2023;18:e0282576.
    PubMed     Abstract available
    
    
    
63. 
    Expression of Concern: Neoadjuvant chemotherapy versus primary debulking surgery in advanced epithelial ovarian cancer: A meta-analysis of peri-operative outcome.
    PLoS One. 2023;18:e0285545.
    PubMed    
    
    
    
64. WU X, Lu W, Jiang C, Zhang D, et al
    Effect of ERCC1 polymorphisms on the response to platinum-based chemotherapy: A systematic review and meta-analysis based on Asian population.
    PLoS One. 2023;18:e0284825.
    PubMed     Abstract available
    
    
    
65. ANCHOORI RK, Anchoori V, Lam B, Tseng SH, et al
    Development and anticancer properties of Up284, a spirocyclic candidate ADRM1/RPN13 inhibitor.
    PLoS One. 2023;18:e0285221.
    PubMed     Abstract available
    
    
    
66. LIU H, Ma S, Chen X, Wu H, et al
    Diagnostic accuracy of the Copenhagen Index in ovarian malignancy: A meta-analysis.
    PLoS One. 2023;18:e0286650.
    PubMed     Abstract available
    
    
    
67. CHEN B, Lu X, Zhou Q, Chen Q, et al
    PAXIP1-AS1 is associated with immune infiltration and predicts poor prognosis in ovarian cancer.
    PLoS One. 2023;18:e0290031.
    PubMed     Abstract available
    
    
    
68. MOATAMED NA, Vahdatshariatpanahi S, Gjertson DW, Sachs CR, et al
    Androgen receptor and its correlation with estrogen and progesterone receptors, aimed for identification of cases for future anti-androgen therapy in endometrial cancers.
    PLoS One. 2023;18:e0291361.
    PubMed     Abstract available
    
    
    
69. MUHAMMAD S, Azwan RJ, Rita RS, Susanti R, et al
    The Role of Interleukin 6 (IL6), Cancer Antigen-125 (CA-125), and Human Epididymis Protein 4 (HE4) to predict tumor resectability in the advanced epithelial ovarian cancer patients.
    PLoS One. 2023;18:e0292282.
    PubMed     Abstract available
    
    
    
70. LEE B, Chang SJ, Kwon BS, Son JH, et al
    Impact of PARP inhibitor maintenance therapy in newly diagnosed advanced epithelial ovarian cancer: A meta-analysis.
    PLoS One. 2023;18:e0294647.
    PubMed     Abstract available
    
    
    
71. ROBERTSON SE, Yasukawa M, Marchion DC, Xiong Y, et al
    Prevalence of viral DNA in high-grade serous epithelial ovarian cancer and correlation with clinical outcomes.
    PLoS One. 2023;18:e0294448.
    PubMed     Abstract available
    
    
    
72. 
    Retraction: SOX2 Enhances the Migration and Invasion of Ovarian Cancer Cells via Src Kinase.
    PLoS One. 2023;18:e0295163.
    PubMed    
    
    
    
73. TAO F, Ruan S, Liu W, Wang L, et al
    Correction: Fuling Granule, a Traditional Chinese Medicine Compound, Suppresses Cell Proliferation and TGFbeta-Induced EMT in Ovarian Cancer.
    PLoS One. 2023;18:e0296410.
    PubMed     Abstract available
    
    

Thank you for your interest in scientific medicine.

AMEDEO Ovarian Neoplasms is free of charge.